Ozempic and Wegovy has been prescribed to Yorkshire patients hundreds of times in the past year - and it's not for weightloss ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

A gold-standard University College of London study found a type of weight-loss jab had no benefit in alleviating a condition ...

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

Almost 2% of the U.S. population received prescriptions for the weight-loss and diabetes drugs semaglutide and tirzepatide in ...

Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

She's going to have good arms!' I was ten years old and standing in my parents' bathroom when I heard my mother say this.

Novo Nordisk stock reversed a three-day downtrend Wednesday after the weight-loss drugs kingpin leaned on Ozempic for a ...

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...